228 abstracts found.



Results filter



Epigenetics impacts copy number heterogeneity and drug resistant gene selection

Year:

Session type: ,

Johnathan Whetstine1

1Harvard Medical School & Massachusetts General Hospital Cancer Center, Boston, USA




T cells and the immunogenicity of immunotherapy

Year:

Session type: ,

Adrian Hayday1

1King’s College London & The francis Crick Institute, London, UK




Radium-223 for prostate cancer bone metastases: How research can change clinical practice

Year:

Session type: ,

Joe O’Sullivan1,2

1Queen’s University Belfast, Belfast, Northern Ireland, UK,2Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK




Molecularly Targeted Radiation Therapy: Towards Individualised Treatment 

Year:

Session type: ,

Katherine Vallis1

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK




Molecular biomarkers: are they so much better than traditional risk factors and simple biomarkers?

Year:

Session type: ,

Peter Sasieni1

1Queen Mary University of London, London, UK




Gut microbiota and anti-cancer immune responses 

Year:

Session type: ,

Laurence Zitvogel1

1Institut Gustave Roussy and INSERM, Villejuif, France




Genetic dissection of tumor development, therapy response and resistance in mouse models of BRCA1-deficient breast cancer

Year:

Session type: ,

Jos Jonkers1

1Netherlands Cancer Institute, Amsterdam, The Netherlands




Epigenetic reprogramming in mammalian development

Year:

Session type: ,

Wolf Reik1

1Babraham Institute, Cambridge, UK,2Centre for Trophoblast Research, University of Cambridge, Cambridge, UK,3Wellcome Trust Sanger Institute, Cambridge, UK




Epigenetic Targets for Cancer Drug Discovery: Bromodomains and Beyond

Year:

Session type: ,

Mark Bunnage1

1Pfizer, Cambridge, MA, USA




Evolution and drug resistance in cancer.

Year:

Session type: ,

Ultan McDermott1

1Wellcome Trust Sanger Institute, Hinxton, UK


Page 2 of 23« First...2...Last »